Company intelligence / Profile preview
Atara Biotherapeutics
Thousand Oaks, California, United States of Americaatarabio.com ↗
- Ownership
- Public · ATRA
- Employees
- ~153
- Development stage
- Commercial
01
Overview
Atara received FDA Complete Response Letter (CRL) for EBVALLO (tabelecleucel) in January 2025 related to inspection findings at a third-party manufacturer. The FDA has placed a clinical hold on Atara's active INDs including EBVALLO and ATA3219 programs. EBVALLO has received regulatory approval in Europe[7].
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- T-cell immunotherapyallogeneic CAR T therapy
- Industry
- Biotech
02
Drug pipeline
28 assets27 more assets in the full pipeline.
03
Partnerships
Pierre Fabre LaboratoriesMemorial Sloan Kettering Cancer CenterQIMR Berghofer
04
Financials
- Market cap
- $79.9M
- Total revenue
- $120.8M
- Enterprise value
- $79.9M
Beyond the preview
Go deeper on Atara Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atara Biotherapeutics.